Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p.

The Neuromed site is conducting studies on inflammatory bowel conditions, notably moderate to severe ulcerative colitis, aiming to assess long‑term safety and therapeutic benefit of novel oral agents.

• Evaluation of disease remission rates
• Impact on quality of life
• Biomarker analysis for treatment response

With a total of 36 trials and 11 investigators, the Lublin‑based centre contributes to advancing gastrointestinal therapy in Poland.

Research at Neuromed includes autoimmune disorders such as generalized myasthenia gravis and primary immune thrombocytopenia, focusing on new antibody‑targeted treatments and safety profiling.

• Assessment of muscle strength improvement
• Platelet count stabilization
• Evaluation of immunoglobulin replacement strategies

The hospital’s multidisciplinary team evaluates innovative immunotherapies to enhance patient outcomes.

The centre is active in oncology trials, particularly for non‑small cell lung cancer with EGFR mutations and HER2‑positive breast cancer, testing targeted agents and combination regimens.

• Progression‑free survival analysis
• Response rates to novel biologics
• Safety monitoring of combination therapies

Leveraging its hospital setting, Neuromed supports cutting‑edge cancer research for patients across the region.

Studies at Neuromed address movement and seizure disorders, including Parkinson's disease with motor fluctuations and focal epilepsy, evaluating new oral and injectable therapies.

• Reduction in tremor severity
• Decrease in seizure frequency
• Improvement in daily functional capacity

The site’s neurologists collaborate with 11 investigators to advance neuro‑therapeutic options.

In the respiratory domain, Neuromed focuses on advanced lung cancers, studying advanced/metastatic non‑small cell lung cancer and exploring sequential chemotherapy‑immunotherapy approaches.

• Evaluation of overall survival benefit
• Assessment of treatment tolerability
• Biomarker-driven patient selection

These trials complement the centre’s broader oncology program and serve the Lublin patient community.

The facility investigates dermatologic reactions linked to cancer therapy, such as skin toxicities associated with epidermal growth factor receptor inhibitors, aiming to improve management and patient comfort.

• Severity grading of acneiform rash
• Efficacy of topical interventions
• Quality‑of‑life outcomes

By integrating dermatology expertise, Neuromed enhances supportive care for oncology patients.

Clinical research at Neuromed includes neuropsychiatric conditions, notably agitation associated with Alzheimer's disease and psychosis in dementia, testing novel oral compounds for symptom control.

• Changes in agitation scores
• Improvement in psychosis rating scales
• Long‑term safety in elderly participants

These trials reflect the centre’s commitment to improving mental health care for older adults in Poland.